BeOne Medicines Ltd. Revenue From Contract With Customer Excluding Assessed Tax

• BeOne Medicines Ltd. showed an increase of +40.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), BeOne Medicines Ltd.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 499,248.9%.
• Historical annual values: Fiscal year 2025: $5.34 billion | Fiscal year 2024: $3.81 billion | Fiscal year 2023: $2.46 billion | Fiscal year 2022: $1.42 billion | Fiscal year 2021: $1.18 billion | Fiscal year 2020: $308.87 million | Fiscal year 2019: $428.21 million | Fiscal year 2018: $198.22 million | Fiscal year 2017: $238.39 million | Fiscal year 2016: $1.07 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026